Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.34

0.53 (0.32%)

16:13
10/03/16
10/03
16:13
10/03/16
16:13

Amgen: JCO publishes 'positive' results from study of BLINCYTO

Amgen announced that the Journal of Clinical Oncology published results from the Phase 1/2 '205 single-arm trial evaluating BLINCYTO in pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Based on data from an exploratory pooled analysis of 70 patients who received the recommended dose of BLINCYTO in the Phase 1 or Phase 2 portions of the study, 27 patients (39%, 95% confidence interval, 27%-51%) achieved complete remission within the first two cycles. The most frequent grade greater than or equal to 3 adverse events among the patients who received the recommended dose were anemia (36%), thrombocytopenia (21%), febrile neutropenia (17%), hypokalemia (17%) and neutropenia (17%). The most common AEs overall were pyrexia (80%), anemia (41%), nausea (33%) and headache (30%).

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.34

0.53 (0.32%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

UPS

UPS

$107.62

0.26 (0.24%)

17:38
04/26/17
04/26
17:38
04/26/17
17:38
Hot Stocks
UPS awarded $2.35B government contract »

United Parcel Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

CSTR

CapStar Financial

$18.01

-0.26 (-1.42%)

17:38
04/26/17
04/26
17:38
04/26/17
17:38
Earnings
CapStar Financial reports Q1 reports Q1 EPS 3c, consensus 19c »

Fully diluted earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

  • 11

    May

  • 07

    Jun

FDX

FedEx

$189.58

0.61 (0.32%)

17:37
04/26/17
04/26
17:37
04/26/17
17:37
Hot Stocks
FedEx awarded $2.35B government contract »

Federal Express Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

  • 09

    May

TCB

TCF Financial

$17.24

0.21 (1.23%)

17:36
04/26/17
04/26
17:36
04/26/17
17:36
Hot Stocks
TCF Financial to change NYSE ticker to 'TCF' from 'TCB' »

TCF Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

UPL

Ultra Petroleum

$11.17

0.2 (1.82%)

17:34
04/26/17
04/26
17:34
04/26/17
17:34
Syndicate
Breaking Syndicate news story on Ultra Petroleum »

Ultra Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CAVM

Cavium

$70.93

-0.31 (-0.44%)

17:33
04/26/17
04/26
17:33
04/26/17
17:33
Earnings
Cavium sees Q2 adjusted EPS 64c-66c, consensus 62c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 17

    May

RICK

RCI Hospitality

$17.16

0.29 (1.72%)

17:29
04/26/17
04/26
17:29
04/26/17
17:29
Hot Stocks
RCI Hospitality acquires assets of St. Louis real estate and gentlemen's club »

RCI Hospitality acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MTGE

MTGE Investment Corp.

$17.85

0.15 (0.85%)

, AGNC

AGNC Investment

$20.80

-0.07 (-0.34%)

17:27
04/26/17
04/26
17:27
04/26/17
17:27
Hot Stocks
AGNC Investment may invest in MTGE Investment Corp. common stock »

AGNC Investment's…

MTGE

MTGE Investment Corp.

$17.85

0.15 (0.85%)

AGNC

AGNC Investment

$20.80

-0.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 04

    May

LVS

Las Vegas Sands

$59.26

0.79 (1.35%)

17:26
04/26/17
04/26
17:26
04/26/17
17:26
Hot Stocks
Las Vegas Sands reports Q1 Venetian Macao net revenue down 1.1% to $741M »

Reports Q1 Venetian Macao…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

DEI

Douglas Emmett

$38.25

-0.56 (-1.44%)

17:22
04/26/17
04/26
17:22
04/26/17
17:22
Hot Stocks
Douglas Emmett acquires two Santa Monica office buildings for $352.8M »

Douglas Emmett has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 01

    Jun

PEGI

Pattern Energy

$22.24

0.08 (0.36%)

17:21
04/26/17
04/26
17:21
04/26/17
17:21
Hot Stocks
Pattern Energy acquires 324 megawatt Broadview Wind in NM »

Pattern Energy Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 01

    Jun

CSLT

Castlight Health

$4.15

0.05 (1.22%)

17:20
04/26/17
04/26
17:20
04/26/17
17:20
Earnings
Castlight Health sees 2017 non-GAAP EPS (28c)-(24c), consensus (14c) »

Sees 2017 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

KRA

Kraton Performance

$33.14

-0.26 (-0.78%)

17:20
04/26/17
04/26
17:20
04/26/17
17:20
Hot Stocks
Kraton Performance sees FY17 adjusted EBITDA about $350M »

Expects to reduce net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

KRA

Kraton Performance

$33.14

-0.26 (-0.78%)

17:19
04/26/17
04/26
17:19
04/26/17
17:19
Earnings
Kraton Performance reports Q1 adjusted EPS (15c), consensus (20c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

GG

Goldcorp

$14.53

0.17 (1.18%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Earnings
Goldcorp reports Q1 EPS 20c, consensus 8c »

Reports Q1 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CSLT

Castlight Health

$4.15

0.05 (1.22%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Earnings
Castlight Health reports Q1 non-GAAP EPS (5c), consensus (5c) »

Reports Q1 revenue $27.7,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

HUBG

Hub Group

$40.15

-0.25 (-0.62%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Hot Stocks
Hub Group sees FY17 CapEx $90M-$100M »

Says truck brokerage and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 10

    May

CNI

Canadian National

$72.39

-0.71 (-0.97%)

17:17
04/26/17
04/26
17:17
04/26/17
17:17
Hot Stocks
Canadian National to purchase shares under a specific share repurchase program »

CN announced that it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKG

Packaging Corp.

$94.54

0.18 (0.19%)

17:17
04/26/17
04/26
17:17
04/26/17
17:17
Earnings
Packaging Corp.reports Q1 EPS $1.27, consensus $1.23 »

Reports Q1 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MAA

MAA

$101.00

-0.47 (-0.46%)

17:16
04/26/17
04/26
17:16
04/26/17
17:16
Earnings
MAA sees 2017 EPS $2.54-$2.74, consensus $2.29 »

Sees 2017 FFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MKL

Markel

$978.01

-2.31 (-0.24%)

17:15
04/26/17
04/26
17:15
04/26/17
17:15
Earnings
Markel reports Q1 diluted EPS $3.90, may not compare to consensus $4.80 »

Markel reported book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SSW

Seaspan

$6.56

0.29 (4.63%)

17:15
04/26/17
04/26
17:15
04/26/17
17:15
Earnings
Seaspan reports Q1 normalized EPS 15c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MAA

MAA

$101.00

-0.47 (-0.46%)

17:14
04/26/17
04/26
17:14
04/26/17
17:14
Earnings
MAA reports Q1 EPS 36c with items, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

INDB

Independent Bank

$66.50

0.7 (1.06%)

17:12
04/26/17
04/26
17:12
04/26/17
17:12
Hot Stocks
Independent Bank says receives all regulatory approvals for Island merger »

Independent Bank and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 18

    May

CRY

CryoLife

$16.75

0.5 (3.08%)

17:11
04/26/17
04/26
17:11
04/26/17
17:11
Earnings
CryoLife sees FY17 adjusted EPS 40c-43c, consensus 41c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.